Juno Therapeutics Inc., a biopharmaceutical company developing cellular immunotherapies for the treatment of cancer, released additional data from the TRANSCEND study of JCAR017 (lisocabtagene maraleucel; liso-cel) in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in a presentation at the 59th American Society of Hematology Annual Meeting and Exposition.
Long-term data on patients treated with a standard chemoimmunotherapy combination show relapse rates dropped over time and 70% of patients were still alive 15 years later, with an overall cure rate estimated at 42% of patients treated, according to a study led by scientists at SWOG, Fred Hutch Cancer Center, and the University of Rochester Medical Center.
